According to the Northeast Pharmaceutical announcement, according to the relevant notice, the “National Essential Drug Catalogue” will come into effect on September 1, 2026, and the company's wholly-owned subsidiary Daiichi Pharmaceutical and its holding subsidiary, Shide Pharmaceutical, have added 14 new product regulations. After being included, it is beneficial for pharmaceuticals to be distributed and used in medical institutions at all levels. It has a positive effect on the company's long-term development, but there is uncertainty about the impact on current business performance, and investors are reminded to pay attention to risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.